This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Amniotics Management

Management Kriterienprüfungen 2/4

Amniotics' CEO ist Marcus Larsson , ernannt in Aug 2022, hat eine Amtszeit von 1.83 Jahren. besitzt direkt 10.19% der Aktien des Unternehmens, im Wert von SEK1.25M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.8 Jahre bzw. 3.4 Jahre.

Wichtige Informationen

Marcus Larsson

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.1yrs
Eigentum des Geschäftsführers	20.4%
Durchschnittliche Amtszeit des Managements	2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.7yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Marcus Larsson (51 yo)

2.1yrs

Amtszeit

Mr. Marcus Larsson, Ph D., has been a Director of Amniotics AB (publ) since 2015 and serves as its Chief Executive Officer from August 2022. He is also Chairman of the Board of Camurus Lipid Research Found...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Marcus Larsson	Founding Member	2.1yrs	keine Daten	20.38% SEK 3.0m
Gerton Jonsson	Chief Financial Officer	1.3yrs	keine Daten	keine Daten
Jan Talts	Chief Operating Officer	7.7yrs	keine Daten	0.27% SEK 39.3k
Sidonie Karlsson	Head of Manufacturing	no data	keine Daten	keine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: AMNIDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Marcus Larsson	Founding Member	9.7yrs	keine Daten	20.38% SEK 3.0m
Peter Jensen	Independent Chairman of the Board	3.7yrs	keine Daten	0.91% SEK 135.0k
Ingrid Heiman	Independent Director	3.7yrs	keine Daten	0.055% SEK 8.1k
Fredrik Tiberg	Independent Director	3.7yrs	keine Daten	2.6% SEK 383.6k
Christopher Bravery	Independent Director	3.7yrs	keine Daten	keine Daten

3.7yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: AMNIDie Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

This company listing is no longer active

Amniotics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Amniotics AB (publ), Annual General Meeting, Jun 28, 2024

Amniotics AB (publ), Annual General Meeting, May 22, 2024

Founding Member exercised options to buy kr949k worth of stock.

Amniotics AB (publ), Annual General Meeting, May 22, 2023

High number of new and inexperienced directors

Amniotics AB (Publ) Announces Executive Changes

Recent updates

Amniotics Applies for Delisting from Nasdaq First North Growth Market

Amniotics AB (publ), Annual General Meeting, Jun 28, 2024

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Amniotics AB (publ) to Report First Half, 2024 Results on Aug 20, 2024

Amniotics AB (publ), Annual General Meeting, May 22, 2024

No longer forecast to breakeven

New minor risk - Profitability

Amniotics AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Amniotics AB (publ) Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation

Amniotics AB (publ) has completed a Composite Units Offering.

Amniotics AB (publ) has completed a Composite Units Offering.

Amniotics AB (publ) Receives Final Clinical Study Report for the Phase Ib Clinical Trial

New major risk - Financial position

New minor risk - Financial position

Founding Member exercised options to buy kr949k worth of stock.

Amniotics AB (publ) Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem

Amniotics AB (publ), Annual General Meeting, May 22, 2023

Forecast to breakeven in 2024

Amniotics AB (publ) Completes Phase Ib Study of PulmoStem

High number of new and inexperienced directors

Amniotics AB (publ) Invites by European Innovation Council to Finalise Grant Agreement with the as Part of Consortium Set to Receive Grant of EUR 3.8 Million from the EIC Pathfinder Programme

Amniotics AB (publ) Announces First Patient Dosed in Phase Ib Study with PulmoStem to Treat Severe Viral Lung Disease

Amniotics Phase Ib Study of Pulmostem™ to Include Broader Patient Population

Amniotics AB (Publ) Announces Executive Changes

High number of new and inexperienced directors

Amniotics AB (publ) Phase I/II Study of PulmoStem™ in Hospitalized COVID-19 Patients Ready to Start

Amniotics AB (Publ) Announces the Resignation of Anders Månsson from the Board

Amniotics Receives Approval for Phase I/II Study of Pulmostem in Hospitalized Covid-19 Patients

Amniotics Secures Funding of SEK 4.8 Million from Vinnova to Develop Stem Cell Therapies

Amniotics submits CTA for Phase I/II trial in COVID-19 patients with PulmoStemTM

Amniotics Joins Vinnova Funded ’CAMP’ ’ to Improve Outcome of Lung Transplantations with Pulmostem™

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter